By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Genzyme Corporation 

500 Kendall Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-252-7500 Fax: 617-252-7600


About Genzyme

Genzyme is committed to discovering and delivering transformative therapies for patients with rare and special unmet medical needs, providing hope where there was none before.

Genzyme has pioneered the development and delivery of transformative therapies for over 30 years. Founded in 1981 in Boston, Massachusetts, Genzyme evolved from a tiny start-up with just a handful of employees to one of the world's leading biotech companies. Acquired by Sanofi in 2011, Genzyme now benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients.

Genzyme has long been known for our expertise in the class of rare genetic diseases known as lysosomal storage disorders (LSDs). LSDs remain the heart of our company today, but we have also expanded – through both in-house development and strategic acquisitions and partnerships – to other disease areas such as thyroid cancer and multiple sclerosis.

Learn more at

Follow our jobs on Twitter

Follow us on LinkedIn

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets, and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Key Statistics

Ownership: Subsidiary

Web Site: Sanofi Genzyme
Symbol: SNY



Medtronic  Cardiac Cell Therapy

Cambridge Antibody Technology Group PLC   Antibodies against TGF-ß

Dyax  Hereditary Angioedema


Company News
Sanofi Genzyme (SNY) Touts Long-Term Data for Multiple Sclerosis Drug Lemtrada 10/8/2015 6:06:37 AM
Sanofi Genzyme (SNY) New Analysis Suggests Aubagio (teriflunomide) Slows Brain Atrophy In People With Relapsing Multiple Sclerosis 10/7/2015 12:03:22 PM
Sanofi Genzyme (SNY) Introduces “Vs.MS,” A Global Initiative Aimed At Uncovering The Often Unspoken Challenges Of MS To Drive Better Informed Care 10/5/2015 8:17:59 AM
Alnylam (ALNY) And Sanofi Genzyme (SNY) Announce That Genzyme Opts Into ALN-AT3 Hemophilia Program For Development And Commercialization Outside Of North America And Western Europe 10/1/2015 11:35:33 AM
More Than 50 Presentations Of New Data From Sanofi Genzyme (SNY)’s Multiple Sclerosis Franchise To Be Featured At ECTRIMS 9/23/2015 10:28:22 AM
Sanofi Genzyme (SNY) Pays $32.5 Million to Resolve Criminal Seprafilm Lawsuit 9/4/2015 6:35:06 AM
Sanofi Genzyme (SNY) Launches Fifth Annual Patient Advocacy Leadership (PAL) Awards Program 7/29/2015 10:55:48 AM
Why Sanofi Genzyme (SNY) Isn't Threatened By Amicus (FOLD) 7/21/2015 6:14:31 AM
How Genzyme (GENZ) Became A Source Of Biotech Executives 7/13/2015 6:59:36 AM
Genzyme (GENZ) Initiates Phase I/II Clinical Trial to Evaluate Olipudase Alfa in Pediatric Patients 6/15/2015 10:51:07 AM